A grandfather struggled with treatment for late-stage pancreatic cancer - until a clinical trial helped him beat the odds

Key Points:

• Hernando Salcedo, an 83-year-old diagnosed with Stage III pancreatic cancer, initially experienced severe side effects from traditional chemotherapy, including weight loss and inability to function normally.
• Salcedo was enrolled in a clinical trial at Miami Cancer Institute testing RenovoRX's RenovoCath system, a catheter-based chemotherapy delivery device designed to target tumors more precisely and reduce systemic side effects.
• The RenovoCath system isolates blood flow to the tumor area, allowing localized chemotherapy delivery, which clinical data showed reduces adverse effects by 65% and extends survival by six months compared to traditional methods.
• After switching to the catheter-based treatment, Salcedo reported significant improvement, with minimal side effects and stable cancer progression, enabling him to regain quality of life and participate in family events.
• The RenovoCath device is FDA-cleared, with ongoing research and final trial results expected in late 2027, offering hope for improved treatment outcomes in Stage III pancreatic cancer patients.